Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALK202
- Development stage
- Phase 2
- Lead developer
- Allink Biotherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ALK202 is a proprietary bispecific antibody-drug conjugate (ADC) developed by Shanghai Allink Biotherapeutics for the treatment of advanced solid tumors. It targets both the epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-MET), two proteins frequently implicated in tumor progression, metastasis, and resistance to single-target therapies. By simultaneously inhibiting EGFR and c-MET, ALK202 aims to overcome resistance mechanisms associated with monotherapies and enhance antitumor efficacy. The ADC incorporates a topoisomerase inhibitor payload and utilizes common light chain technology to prevent mispairing during antibody assembly, optimizing binding affinities while reducing target-related toxicities. As of early 2025, ALK202 is being evaluated in global Phase I clinical trials for patients with advanced solid tumors who have progressed on standard therapies[1][2][3][4][5].
- Other names
- ALK 202ALK202ALK-202
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on ALK202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALK202.